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Abstract The essential function of sterol regulatory ele-
ment-binding proteins (SREBPs) in cellular lipid metabo-
lism and homeostasis has been recognized for a long time,
and the basic biological pathway involving SREBPs has
been well described; however, a rapidly growing number of
studies reveal the complex regulation of these SREBP
transcription factors at multiple levels. This regulation
allows the integration of signals of diverse pathways
involving nutrients, contributing to cellular lipid and energy
homeostasis. This review attempts to integrate this knowl-
edge. The description of the SREBP pathway is Web-linked
as it refers to the online version of the pathway on
wikipathways.org, which is interactively linked to genom-
ics databases and literature. This allows a more extensive
study of the pathway through reviewing these links.
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Introduction
Sterol regulatory element-binding proteins (SREBPs) play
an important role in the regulation of the intracellular cho-
lesterol concentration and in overall lipid homeostasis. Since
lipids and cholesterol are important components of cellular
membranes and precursors for steroid hormones, bile salts,
and essential signaling molecules, a tight regulation is vital.
SREBPs provide a negative feedback mechanism by sensing
the intracellular levels of cholesterol. SREBPs function as
transcription factors, and upon activation, by low levels of
cholesterol, they stimulate the expression of genes coding for
proteins involved in the synthesis of cholesterol and fatty
acids and in the uptake of lipoproteins (Brown and Goldstein
1997). The basic signaling pathway affected by SREBPs has
been elucidated in great detail. However, regulation of
SREBPs themselves is proven to be very complex. In the last
few years, research has brought new insights regarding this
regulation and the interaction with other nutrients and hor-
mones that play a role in energy homeostasis. Recent studies
also implicated the SREBP pathway to be important in the
development of a range of pathological conditions, associ-
ated with obesity and the metabolic syndrome, like liver
steatosis and hyperlipidemia (Moon et al. 2012). It has also
been described that SREBP has a role in several physiolog-
ical cellular processes not directly related with lipid
homeostasis, like cell growth and innate immunity (Jeon and
Osborne 2012). As the insight in the SREBP pathway
becomes more and more complex, integration of the differ-
ent aspects of this knowledge is vital. We will describe the
SREBP protein and its isoforms, to continue with a
description of the current view on the molecular basis of the
SREBP pathway, its complex regulation and its physiolog-
ical function. In this review, we are applying a pathway
approach to investigate the function and regulation of the
SREBP proteins in lipid-metabolism-related pathways.
SREBP pathway
The description of the SREBP pathway in this review will
especially focus on the role of the SREBP proteins in lipid-
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metabolism-related pathways. A graphical representation
of the SREBP pathway (see Fig. 1) can be found on Wi-
kiPathways, a platform for community-based curation of
biological pathways (Pico et al. 2008; Kelder et al. 2012).
This pathway is a mammalian meta-pathway combining
data from mouse, rat, and human studies. The description
of the SREBP pathway will refer to this pathway repre-
sentation on WikiPathways. The interactive pathway
viewer on WikiPathways enables the user to zoom, pan,
and browse to get detailed information on pathway ele-
ments in external databases and thereby allowing a more
extensive study (Kelder et al. 2012). The pathway can be
found at: http://wikipathways.org/index.php/Pathway:
WP1982. The specific version we used for this review was:
http://wikipathways.org/instance/WP1982_r59430. Vari-
ous elements of the pathway (gene products, metabolites,
interactions, and the pathway as a whole) are linked to
literature references using Pubmed IDs. The gene products
are among others linked to genomics databases like EN-
SEMBL (Flicek et al. 2011), Entrez (Maglott et al. 2011)
and UniProt (Consortium 2012) and to databases providing
information on biological function and the role in diseases,
including Gene Ontology (Ashburner et al. 2000) and
OMIM (Borate and Baxevanis 2009). The metabolites are
linked to metabolite databases like HMDB (Wishart et al.
2013) and ChEBI (de Matos et al. 2010).
The SREBP family
The SREBP family consists of three subtypes: SREBP-1a
and SREBP-1c, which are the result of alternative promoter
usage and transcription start sites in the SREBF1 gene, and
SREBP-2. All three subtypes were identified by cDNA
cloning (Yokoyama et al. 1993; Hua et al. 1993). SREBPs
are transcription factors that bind to the sterol regulatory
element (SRE) (Yokoyama et al. 1993). They are synthe-
sized as endoplasmic reticulum (ER) membrane proteins.
The SREBP protein consists of three domains: a N-termi-
nal domain which has approximately 480 amino acids, in
the middle a hydrophobic region of 80 amino acids con-
taining two membrane-spanning domains and a C-terminal
regulatory domain of 590 amino acids (Brown and Gold-
stein 1997). They are oriented in a hairpin fashion in the
membranes of the ER and the nuclear envelope, in which
the N-terminal and C-terminal project into the cytoplasm.
The N-terminal domain is a basic-helix-loop-helix leu-
cine zipper (bHLH-Zip). This domain is the functionally
active portion of the SREBP and functions as the tran-
scription factor. The N-terminal domain starts with an
acidic domain that clusters acidic residues and functions as
a transactivation domain. Deletion of this acidic domain
converts SREBP-1 from an activator to an inhibitor of
transcription (Sato et al. 1994). The acidic domain is
Fig. 1 The SREBP pathway on WikiPathways
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followed by a region of which the function is unknown. In
SREBP-1, this region is proline and serine rich, and in
SREBP-2, this region is proline, serine, glutamine, and
glycine rich. This region is then followed by the bHLH-Zip
domain (Brown and Goldstein 1997). Figure 2 gives an
overview of the different protein domains of the SREBP
isoforms.
The high similarity among the N-terminal domains of the
isoforms of SREBP results in the ability of all isoforms to
activate all of the target genes identified so far, but with
different efficiencies (Shimano 2001). Given that SREBP-
1c has a shorter transactivation domain, this isoform is a
less potent transcription factor than SREBP-1a and SREBP-
2 (Shimano et al. 1997). Several in vivo studies obtained
insight in the distinct roles of the SREBP isoforms. In
transgenic mice that overexpress a truncated, active nuclear
form of SREBP-2 in liver and adipose tissue, it was shown
that SREBP-2 is a relatively selective activator of choles-
terol synthesis, as opposed to fatty acid synthesis in these
tissues (Horton et al. 1998). SREBP-1 knockout mice
showed a significant decrease in mRNA coding for fatty
acid synthesis enzymes. There was also a significant
increase in cholesterol synthesis, but this was due to acti-
vation of SREBP-2, which compensated for the lack of
SREBP-1 (Shimano et al. 1999). In general, SREBP-1 is
relatively selective for lipogenic genes and SREBP-2 for
cholesterogenic genes. This is due to differences among the
SREBP isoforms in specificity for SREBP target promoters
(Amemiya-Kudo et al. 2002; Pai et al. 1998).
Activation of SREBP
Since SREBP is bound to the ER membrane, the N-terminal
domain must be released before SREBP can activate its
target genes in the nucleus. This requires a two-step prote-
olytic process, which takes place in the Golgi apparatus.
Therefore, the SREBP is first transported to the Golgi
apparatus. Important for the regulation of the cleavage of
SREBP is another ER membrane-embedded protein named
SREBP cleavage-activating protein (SCAP). In mice with a
SCAP-deficient liver, no nuclear form of SREBP was found,
and they showed an 80 % decrease in basal rates of choles-
terol and fatty acid synthesis in the liver (Matsuda et al.
2001). SCAP has an N-terminal domain of 730 amino acids
which has eight membrane-spanning regions separated by
short hydrophilic loops, which include a sterol-sensing
domain (SSD). This domain is similar to the sterol-sensing
domain found in other proteins which interact with sterols:
3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA)
reductase, the Niemann-Pick disease type C1 protein and
Patched (Hua et al. 1996). The C-terminal domain is a
hydrophilic region of 546 amino acids containing 4 repeats
of a tryptophan–aspartate repeat, WD. Both SREBP-1 and
SREBP-2 form a complex with the SCAP protein on the ER
membrane by binding of the WD region in SCAP to the
C-terminal domain of SREBP. When there are enough
sterols present in cells, cholesterol can bind directly to the
sterol-sensing domain of SCAP, which then undergoes a
conformational change. This conformation favors the bind-
ing of SCAP to another ER membrane protein named insulin-
induced gene (Insig), which blocks translocation of the
SREBP–SCAP complex to the Golgi apparatus, where the
proteolytic activation takes place (Yang et al. 2002). This can
be seen in the upper left corner of the pathway representation.
The red arrow indicates the negative effect of cholesterol on
SREBP stimulation by stimulating the binding of Insig to the
SREBP–SCAP complex. Metabolites, like cholesterol, are
indicated in blue boxes in the pathway representation.
There are two Insig isoforms, Insig-1 and Insig-2, which
are both polytopic ER membrane proteins. They play an
important role in the control of lipid synthesis, not only by
binding to the SCAP protein. Insigs also bind to HMG-CoA
reductase, which is the rate-limiting enzyme in the synthesis
of cholesterol. The binding of Insig to HMG-CoA reductase
induces the ubiquitination and proteolysis of this enzyme,
whereas binding of Insig to SCAP leads to ER retention (Cao
et al. 2007; Sever et al. 2003). The dual function of Insig in
cholesterol metabolism is discussed in more detail in (Ben-
goechea-Alonso and Ericsson 2007). Insig-1 and Insig-2
demonstrate an amino acid identity of 59 % and are both
embedded in the ER membrane by six membrane-spanning
domains (Yabe et al. 2002). The regulation and the relative
stability of the two isoforms differ. Insig-1 is itself a target of
SREBP, whereas Insig-2a has been shown to be suppressed
by insulin in hepatic cells (Yabe et al. 2003; Yellaturu et al.
2009b). The exact mechanism of the regulation of Insig by
insulin remains unclear and is therefore visualized in the
WikiPathways pathway using a dashed arrow. The Insig-1
protein is quite unstable and is degraded by the ubiquitin–
proteasome pathway, whereas insig-2 is a relatively stable
protein, which is constitutively expressed at low levels. In
transgenic mice that overexpress human Insig-1 in the liver,
the levels of all nuclear SREBPs (nSREBPs) were reduced,
Fig. 2 Protein domains of the SREBP isoforms. The structure of
SREBP-1c is highly similar to SREBP-1a; SREBP-1c had a shorter
transactivation domain in the N-terminus (Brown and Goldstein 1997)
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which shows that Insig inhibits SREBP processing (Engel-
king et al. 2004).
Upon sterol deprivation, the SREBP–SCAP complex
dissociates from Insig and moves to the Golgi apparatus, a
process that is discussed in more detail in the next section.
Insig-1 is then ubiquitinated on lysines 156 and 158 by the
membrane-bound ubiquitin ligase gp78. This ubiquitin
ligase has a high affinity for Insig-1, and degradation of
Insig-1 in a cholesterol-rich environment is probably pre-
vented by binding competition between gp78 and SCAP
(Lee et al. 2006). Insig-1 is subsequently degraded in
proteasomes, providing a positive feedback mechanism on
the activation of SREBP. nSREBPs activate the genes for
cholesterol synthesis and uptake and stimulate the pro-
duction of Insig-1. This upregulation can be seen in the
pathway on the right in blue arrows. The new cholesterol
and Insig-1 bind the SREBP–SCAP complex and the
complex remains in the ER (Gong et al. 2006).
The cholesterol regulatory system is controlled not only
by its end product cholesterol but also by oxysterols. Ox-
ysterols are derivatives of cholesterol which have extra
keto- or hydroxyl groups. Oxysterols were proven to reg-
ulate the interaction of SCAP and Insig, but they do so by a
different mechanism than cholesterol. Cholesterol binds to
SCAP, while oxysterols bind to Insigs. This induces SCAP
to bind to Insig, which inhibits the movement of the
SREBP–SCAP complex to the Golgi apparatus (Radha-
krishnan et al. 2007). Oxysterols are also ligands of the
nuclear liver X receptors (LXRs), which also play an
important role in the cholesterol synthesis. Upon activation
by oxysterols, LXR forms a heterodimer with the retinoid
X receptors (RXRs) which binds to the LXR response
element (LXRE) on target genes. An LXRE has been found
in the proximal promoter region of the rat cytochrome
P450 7A1 (CYP7A1) gene, which codes for an enzyme
responsible for the rate-limiting step in the conversion of
cholesterol to bile acids (Lehmann et al. 1997). However,
in the human gene promotor of CYP7A1, the LXRE
appears to be not conserved. In addition, in human primary
hepatocyte cultures, it has been shown that activation of the
LXR represses CYP7A1 expression, indicating a species-
specific difference in the regulation of cholesterol homeo-
stasis (Goodwin et al. 2003). In addition, LXRs have been
implicated in the upregulation of genes involved in efflux
of cholesterol from the cell, as ATP-binding cassette A1
(ABCA1). LXR/RXR can also bind the SREBP-1c pro-
moter and induce SREBP-1 activation of fatty acid syn-
thesis (Schultz et al. 2000).
ER to Golgi transport
If there are not enough sterols present in the cell, the
SREBP–SCAP complex moves to the Golgi apparatus
through COPII-coated vesicles. The sorting of the complex
in a COPII vesicle is depending on an amino acid sequence
in the SCAP protein. SCAP has a long loop, which projects
into the cytoplasm between the membrane-spanning heli-
ces 6 and 7. In this loop, the hexapeptide MELADL is
found, which is required for the binding of the COPII
proteins Sec23 and Sec24 to the SREBP–SCAP complex.
Clustering of the SREBP–SCAP complex into a COPII
vesicle is initiated by Sar1, a small GTPase that binds to
the ER membrane GTP dependent. This binding is visu-
alized on WikiPathways by a green arrow, which shows
that this is the first step in the cascade toward activation of
transcription by SREBPs. The binding of Sar1 initiates the
binding of Sec23/24, which then recruits Sec13/31. This
heterodimer forms the coat of the vesicle and the vesicle
can bud from the ER membrane (Sun et al. 2005). Inter-
action of SCAP with Insig causes a conformational change
in SCAP which inhibits the interaction of MEDADL with
Sec23/24.
An ER membrane protein named ring finger protein 139,
also called TRC8, shown in the upper right corner on
WikiPathways, was identified as a regulator in the SREBP
pathway. The protein contains a sterol-sensing domain
(SSD) and a RING finger motif, which encodes for an E3
ubiquitin ligase. It is shown that the overexpressing of
TRC8 inhibits SREBP-2 processing. TRC8 is capable of
binding both SREBP-2 and SCAP and a TRC8–SREBP–
SCAP complex is formed. This inhibits the binding of
SCAP to Sec23/24 and blocks transport of the SREBP–
SCAP to the Golgi apparatus. The TRC8 protein in itself is
highly unstable because of self-ubiquitination, which leads
to degradation. When cells were cultured with a lipopro-
tein-deficient serum, the TRC8 protein became stable
(Irisawa et al. 2009). It is thus likely that when the SSD
senses a decline in lipoprotein, it will downregulate the E3
ligase activity. It could provide a brake on the SREBP
processing in conditions of sterol depletion, preventing too
much processing of SREBP (Sato 2010).
Proteolytic cleavage
After fusion of the COPII vesicle with the Golgi apparatus,
the N-terminal of the SREBPs is released by intramem-
brane proteolysis. The processing of SREBP–nSREBP is
shown in the bottom left corner on WikiPathways. The
process is executed by two proteases, membrane-bound
transcription factor peptidase site 1, or Site-1 protease
(S1P), and Site-2 protease (S2P). The process is initiated
when S1P, a membrane-bound serine protease, cleaves the
leucine–serine bond in the sequence RSVLS within the
luminal loop of SREBP (Duncan et al. 1997). This sepa-
rates the two membrane-spanning segments. The next step
is cleavage by S2P, which hydrolyzes a leucine–cysteine
292 Genes Nutr (2013) 8:289–300
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bond in the sequence DRSRILLC. This sequence lies
within the N-terminal membrane-spanning domain, and
cleavage occurs in three residues in this domain (Duncan
et al. 1998). The result is that the N-terminal domain is
released from the SREBP and functions as an active
nSREBP, which migrates to the nucleus to activate target
genes (Brown and Goldstein 1999). It has been proposed
that the cleavage of S1P is required for the cleavage of
S2P, because the separation of SREBP into two halves
causes a conformational change in the first membrane-
spanning domain which allows S2P to be exposed to its
target sequence, thus favoring the cleavage of S2P (Ye
et al. 2000). In addition, it has been demonstrated that
caspase 3, a cysteine protease that is involved in the
induction of apoptosis, releases mature SREBP from the
ER membrane, probably in a sterol-independent manner
(Higgins and Ioannou 2001).
SREBP target
The nSREBPs released during the cleavage reaction travel
into the nucleus. This nuclear transport is mediated by
karyopherin (importin) beta, which interacts with the
bHLH-Zip motif (Nagoshi et al. 1999). Important genes
involved in lipid metabolism that are activated by SREBP
are listed individually on WikiPathways. Besides acti-
vating these target genes, SREBPs also induce transcrip-
tion of the SREBP gene itself, which contains a SRE, and
thus stimulate production of new SREBPs and provide a
positive feedback loop. Although SREBPs mainly activate
target genes, genes with a SRE sequence have been
reported which are repressed by SREBPs. These genes
are, for example, microsomal triglyceride transfer protein
(MTTP) (Sato et al. 1999) and caveolin (Bist et al. 1997).
Since SREBP is active in cases of cholesterol depletion, it
is likely that SREBPs repress these genes, which are
involved in the efflux of cholesterol and the secretion of
lipoproteins (Shimano 2001). The inhibition of genes by
SREBP could be due to an indirect effect, namely through
activation of repressors. For example, in human myotu-
bes, it has been shown that the transcriptional repressor
genes BHLHB2 and BHLHB3 are SREBP-1 target genes,
negatively regulating skeletal muscle development (Lec-
omte et al. 2010).
Activation of the target genes by SREBP requires sev-
eral cofactors. Usually, nuclear transcription factor Y (NF-
Y), Sp1 transcription factor, and CREB-binding protein
(CBP) act as cofactors for SREBP. Binding sites for these
factors are often found in the SREBP target gene promoters
and they are involved in the assembly of the transcription
machinery (Bennett and Osborne 2000). The activator
recruited-cofactor (ARC)-mediated co-activator complex, a
large complex that associates with RNA polymerase II, has
also been found to interact with SREBPs. They have been
shown to use ARC105 to activate target genes (Yang et al.
2006). The peroxisome proliferator-activated receptor-c
coactivator-1 (PGC-1) family functions as important reg-
ulators of lipid metabolism. PCG-1b has been found to
interact with SREBPs and works as a transcriptional co-
activator in the transcription of lipogenic genes (Lin et al.
2005).
Another transcription factor named the YY1 transcrip-
tion factor seems to be negatively involved in the regula-
tion of SREBP target gene activation. It is shown that the
promoters of the HMG-CoA synthase, farnesyl diphosphate
(FPP) synthase, and the low-density lipoprotein (LDL)
receptor contain YY1 binding sites. YY1 seems to repress
SREBP activation by the displacement of NP-Y from the
promoter (Ericsson et al. 1999). Other studies suggest YY1
acts by inhibiting the interaction between Sp1 and SREBP
(Bennett et al. 1999). The physiological role of YY1,
however, is yet to be identified. On WikiPathways, the
cofactors are drawn on a cofactor-binding site in the pro-
moter of the target genes. The green colored boxes show
activators, whereas the red colored boxes represent
repressors.
Interestingly, the SREBF-1 and SREBF-2 gene loci
contain, respectively, miR33b in intron 17 and miR33a in
intron 16. The mature microRNAs differ in only two
nucleotides, but are thought to have a largely overlapping
target gene set (Davalos et al. 2011; Rottiers and Naar
2012). These microRNAs appear to work synergistically
with SREBP in increasing fatty acid synthesis and cho-
lesterol synthesis and uptake (Rayner et al. 2010; Horie
et al. 2010; Gerin et al. 2010). Interestingly, rodents lack
the miR33b gene in the SREBF-1 gene (Rayner et al.
2010). Both miR33a and miRNA33b seem to inhibit the
expression of genes involved in fatty acid degradation, e.g.,
carnitine O-octanoyltransferase (CROT), and genes that
negatively regulate fat production, e.g., insulin receptor
substrate 2 (IRS2) (Rottiers and Naar 2012). In addition,
they also repress expression of ATP-binding cassette
transporter A1 (ABCA1), which normally promotes the
efflux of cholesterol from cells to apolipoprotein A1
(APOA1), leading to high-density lipoprotein (HDL) for-
mation (Horie et al. 2010).
Regulation of the SREBP pathway
Expression and processing of the isoforms of SREBP
in vivo was found to be very complex. The SREBP path-
way is not just regulated on cell level by the intracellular
level of cholesterol, but it can be affected by the nutritional
and hormonal status of the body as a whole.
Several studies provided a link between insulin, glucose,
and SREBPs. It is known that glucose and insulin stimulate
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fatty acid synthesis through activation of hepatic lipogenic
genes. It has been recognized the PI3K/AKT pathway plays
an important role in the regulation of SREBP by insulin. A
range of studies has been done on exploring the effect of
the PI3K/AKT pathway on SREBP, and effects on tran-
scription, activity, processing, and stability have been found
(Krycer et al. 2010). A possible mechanism is that insulin
increases the migration of the SREBP–SCAP complex from
ER to Golgi. Insulin stimulates Akt/PKB-dependent phos-
phorylation of serine and threonine residues of SREBP-1c.
This leads to an increased affinity of the SREBP–SCAP
complex for de COPII proteins, Sar1 and Sec23/24, and a
decreased affinity for Insig, which retains the SREBP–
SCAP complex in the ER membrane (Yellaturu et al.
2009a). It has also been shown that insulin enhances pro-
cessing of SREBP-1c in hepatic cells by stimulation of the
degradation of Insig-2a mRNA, reducing Insig-2a protein
levels (Yellaturu et al. 2009b). The PI3K/AKT pathway
inhibits glycogen synthase kinase 3 (GSK3) through phos-
phorylation. It has been proposed that this diminishes
degradation of mature SREBP-1, since GSK3 has been
shown to promote ubiquitination and proteasomal degra-
dation of SREBP-1 through a phosphorylation cascade;
GSK3 phosphorylates SREBP-1 at Ser-434, whereby it
increases its own affinity for Ser-430 and Thr-426 in
SREBP-1, leading to GSK-3-dependent phosphorylation of
these sites and a binding site for the ubiquitin ligase Fbw7
(Bengoechea-Alonso and Ericsson 2009). One of the major
downstream regulators of the PI3K/AKT pathway is the
mammalian target of rapamycin (mTOR). In the past, it has
been shown that the mTOR complex-1 (mTORC1) posi-
tively regulates the processing of SREBP-1. It was thought
this activation was mediated by the ribosomal protein S6
kinase (RPS6K2), which is phosphorylated by mTORC1
(Duvel et al. 2010). It has recently been shown that insulin-
mediated stimulation of SREBP-1c processing required
mTOR, studied in a hepatic system in which the effect of
insulin on SREBP-1c processing could be dissected from
the effect of insulin on SREBP-1c transcription, described
below. This stimulation of SREBP processing by insulin
could be inhibited by using an inhibitor of p70 ribosomal
S6K, leading to an increase in nSREBP-1c, which was more
likely due to an increased production of nSREBP-1c then
decreased degradation. The mechanisms by which S6K can
lead to increase in nSREBP-1c require further investigation
(Owen et al. 2012; Quinn and Birnbaum 2012).
In addition, it has been suggested that the regulation of
SREBP-1 is achieved by the regulation of the nuclear entry
of phosphatidate phosphatase lipin 1 by mTORC1. Lipins
are involved in triacylglycerol biosynthesis and have a
second function as transcriptional co-activators. Lipins are
sequestered in the cytosol in a hyper-phosphorylated state,
and phosphorylation is induced by mTORC1. Loss of
mTORC1-mediated lipin 1 phosphorylation promotes the
nuclear entry of lipin 1, and this promotes downregulation
of nSREBP, of which the exact mechanism is unknown
(Peterson et al. 2011).
Also, insulin can increase basal transcription of the
SREBP-1c gene. The liver X receptor has been reported to
have a central role in this insulin-mediated activation of
SREBP-1c transcription. In the mouse promoter of
SREBP-1c, two LXR elements have been found. In rat
primary hepatocytes, it was shown that disruption of both
LXREs blunts the effect of insulin on transcription of
SREBP-1c (Chen et al. 2004). In contrast, another study
did not find a major involvement of the LXREs in the
response to insulin, but insulin requires the presence of
SRE in the SREBF-1 promoter and enhanced the binding
of SREBP-1 to its own promoter. However, it should be
noticed that this study made use of a different system based
on HEK293 cells (Dif et al. 2006). cAMP, which can be
activated by glucagon, and the cAMP-dependent kinase,
protein kinase A (PKA) have been shown to suppress
SREBP-1c transcription by phosphorylation of LXR, which
inhibits the DNA binding activity by inhibiting LXR/RXR
dimerization, decreases recruitment of a coactivator, and
enhances the recruitment of a corepressor (Yamamoto et al.
2007). In addition, it has been shown in HepG2 cells that
PKA can phosphorylate SREBP-1a at Ser338, which
reduces DNA binding of SREBP-1c (Lu and Shyy 2006).
These results indicate a role for the cAMP/PKA pathway in
mediating SREBP-1 and hepatic lipogenesis.
It has been shown that the increase in SREBP-1
expression stimulated by insulin can be inhibited by
wortmannin and rapamycin, indicating the PI3K-mTORC1
pathway is involved. In contrast to the stimulation of
SREBP-1c processing by insulin, the increase in SREBP-1
expression by insulin could not be blocked by inhibiting
S6K. This suggests that the regulation of SREBP-1c by
insulin bifurcates downstream of mTORC1, with one arm
controlling the processing of SREBP-1c and the other the
gene expression (Owen et al. 2012; Quinn and Birnbaum
2012). Furthermore, it has been shown that upstream of this
in the liver, by using liver-specific rictor knockout mice,
insulin stimulates mTOR complex-2 (mTORC2), which
phosphorylated Akt at serine 473, leading to SREBP-1c
activation (Hagiwara et al. 2012). Other studies showed
that a glucose-dependent increase in SREBP-1c protein,
shown in the lower right corner of the pathway, was due to
an increase in SREBP-1 mRNA, suggesting that glucose
regulates the expression of SREBP-1c at transcriptional
level (Hasty et al. 2000). In a human renal proximal tubular
cell line, it was shown the glucose-dependent activation of
SREBP was potentially mediated through the PI3K/AKT
pathway (Hao et al. 2011). SREBP-2 levels remained
unchanged when treated with insulin and glucose in the
294 Genes Nutr (2013) 8:289–300
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liver. That insulin only stimulates hepatic SREBP-1, and
not SREBP-2, matches the fact that insulin and SREBP-1
have both been shown to induce lipogenesis. However, in
the brain, it has been shown that in insulin-deficient dia-
betic mice, there is a reduction in the expression of
SREBP-2, suggesting that in the brain, insulin upregulates
SREBP-2 expression (Suzuki et al. 2010). A complete
picture of the regulation of SREBP by insulin and glucose
requires additional studies. In addition, cyclin-dependent
kinase 8 (CDK8) and its regulatory partner cyclin C
(CycC), which are part of the coactivator mediator com-
plexes in mammalian cells, have been identified as regu-
lators of de novo lipogenesis in Drosophila. Site-specific
phosphorylation of nuclear SREBP-1c by CDK8 results in
an enhanced ubiquitination and degradation of nSREBP-
1c. Insulin and feeding decreased the levels of CDK2 and
CycC and enhanced the levels SREBP-1c, indicating
CDK8–CycC acts downstream of insulin in the regulation
of de novo lipogenesis (Zhao et al. 2012).
A crosstalk between SREBP and carbohydrate responsive
element-binding protein (ChREBP) has been found. These
transcription factors appear to work synergistically to reg-
ulate glycolytic and lipogenic gene expression. The phos-
phorylation of glucose to glucose-6-phosphate by hepatic
glucokinase (GK) was found to be essential in the induction
of glycolytic and lipogenic genes (Dentin et al. 2004). SREs
have been found in the GK promoter, which is an indication
that SREBP can activate GK expression after activation by
insulin. In the presence of high glucose, xylulose 5-phos-
phate (X5P) can be formed, which can activate protein
phosphatase 2A (PP2A). This phosphatase can dephos-
phorylate ChREBP, leading to nuclear translocation of this
transcription factor, where it binds to carbohydrate response
element (ChRE) in the promoter of glycolytic and lipogenic
genes. In addition, SREBP-1c can stimulate glycolytic and
lipogenic gene transcription after stimulation by insulin.
Thus, in the presence of high glucose and insulin, ChREBP
and SREBP can work synergistically to activate glycolytic
and lipogenic genes (Dentin et al. 2005).
Activating transcription factor-6 (ATF6) has also been
found to interact with SREBP-2. ATF6 is also an ER
membrane-bound transcription factor, which upon stimu-
lation is translocated from ER to Golgi, where proteolytic
cleavage by S1P and S2P occurs (Chen et al. 2002). ATF6
is stimulated by the accumulation of misfolded or unfolded
proteins and this ER stress could be caused by glucose
deprivation. The cleaved ATF6 translocates to the nucleus
and binds to nSREBP-2 bound to target genes promoters.
The nuclear ATF6 recruits histone deacetylase 1 (HDAC1),
which downregulates SREBP-2 gene expression. The
physiological relevance could be that when glucose is
depleted, lipogenesis and cholesterogenesis are downreg-
ulated to save energy (Zeng et al. 2004).
Alternative regulators of the SREBP pathway are poly-
unsaturated fatty acids (PUFAs), another example of how
diet influences the activation of SREBP. PUFAs have been
known as negative regulators of hepatic lipogenesis and
have an inhibitory effect on the SREBP pathway. PUFAs
appear to suppress the proteolytic processing of SREBP-1c.
Suppression of the proteolytic processing of SREBP in turn
leads to a decrease in SREBP-1c transcription through
lowering SREBP-1c binding to SRE on its own promoter.
The exact molecular mechanism underlying this suppres-
sion still remains unknown, which is shown by the dashed
arrow in the pathway. PUFAs do not seem to affect the
functioning of SREBP-2 (Takeuchi et al. 2010). There are
several reports suggesting LXR is involved in transcrip-
tional regulation of SREBPs by PUFA (Ou et al. 2001;
Yoshikawa et al. 2002). However, several other studies did
not find an involvement of LXR in the regulation by PUFA,
which could be due to different study systems being used
(Takeuchi et al. 2010; Deng et al. 2002). In addition, it has
been shown that unsaturated fatty acids inhibit proteosomal
degradation of Insig-1. Membrane proteins of the ER can
be degraded by the ubiquitination-proteasome system in a
process called ER-associated degradation (ERAD). In this
process, valosin-containing protein (VCP) extracts ubiqui-
tinated proteins from the membrane making the proteins
accessible for degradation in the proteasome. Another
protein, named Ubxd8, recruits VCP to Insig-1. Unsatu-
rated fatty acids (UFAs) appear to block to interaction
between Ubxd8 and VCP, thereby inhibiting the extraction
of Insig-1 from the membrane (Lee et al. 2008).
Recent findings suggest the amino acid glutamine is also
involved the regulation of the gene expression and pro-
cessing of SREBPs, suggesting another link between amino
acid metabolism and lipid metabolism. Glutamine seems to
increase mRNA levels of several SREBP targets. Gluta-
mine aids in the gene expression of SREBP-1 by increasing
the binding of the transcription factor Sp1 to the SREBP-1a
promoter. Glutamine also increases the processing of the
SREBP protein, presumably by stimulating the transport of
the SREBP–SCAP complex from ER to the Golgi appa-
ratus (Inoue et al. 2011).
The NAD?-dependent deacetylase SIRT1 has been
shown to directly deacetylate SREBP-1c, leading to a
decreased stability of the protein and a reduced association
of SREBP-1c with its target genes (Ponugoti et al. 2010).
Furthermore, SIRT1 has been shown to downregulate tar-
get gene expression by SREBP-1c in vivo under fasting
conditions (Walker et al. 2010). Whereas these studied
focuses on the liver, recently, it has been shown that SIRT1
also regulated SREBP-1c expression in skeletal muscle.
Interestingly, the effect of SIRT1 on SREBP-1c expression
was completely abolished when the LXR response ele-
ments in the SREBF-1 promoter were deleted, which
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suggest SIRT1 regulates SREBP-1c expression in muscle
by deacetylation of LXR transcription factors (Defour et al.
2012). In addition, AMP-activated protein kinase (AMPK)
has been shown to directly phosphorylate SREBP-1c and
thereby directly inhibit SREBP-1c processing and translo-
cation to the nucleus in the liver (Li et al. 2011b). Inter-
estingly, there is evidence that AMPK and SIRT1 stimulate
each other and share targets (Ruderman et al. 2010).
A link has also been found between fibroblast growth
factor 21 (FGF21) and SREBP-1c in hepatocytes. FGF21
has been identified as a regulator of energy homeostasis,
glucose, and lipid metabolism. However, little is known
about the regulation or activity of this FGF. It was found
that FGF21 downregulated the transcription of SREBP-1c,
but the processing of SREBP-1c to its mature form was
also diminished. Interestingly, it was found that SREBP-1c
could also inhibit FGF21 expression. Molecular mecha-
nisms and biological relevance of this link remain unclear
for the time being (Zhang et al. 2011).
Recently, the role of retinol binding protein 4 (RBP4) in
lipogenesis has been explored. In HepG2 cells, human
RBP4 induces an increase in mature SREBP-1 and its
nuclear translocation, which was also confirmed in an
in vivo experiment. In addition, treatment of HepG2 cells
with RBP4 leads to a strong upregulation of the expression
and protein levels of PCG-1b. This suggests that RBP4
induces SREBP-1 activation through induction of PCG-1b,
leading to an increase in hepatic lipogenesis (Xia et al.
2013). Earlier, it was already reported that retinoic acid and
retinal can synergize with insulin to induce the expression
of SREBP-1c in primary rat hepatocytes. This was medi-
ated via the retinoid X receptor. This indicated a role of
retinol in regulating hepatic lipogenesis (Li et al. 2011a).
Other roles of SREBP
The important function of SREBP in lipid metabolism led
to these proteins being involved in a variety of pathological
conditions related to lipid metabolism, as steatosis and
hyperlipidemia (Moon et al. 2012). However, several other
functions of SREBP, not directly related to lipid metabo-
lism, have emerged recently. SREBPs have been found to
regulate several cellular processes, including autophagy,
phagocytosis, membrane biogenesis, immunity, hypoxia,
and the cell cycle. SREBP-2 has been found to occupy
promoters of genes that are involved in mediating
autophagy and knockdown of SREBP-2 decreases auto-
phagosome formation in cholesterol-depleted cells, indi-
cating a role for SREBP-2 in autophagy (Seo et al. 2011).
Phagocytosis occurs especially within the phagocytic cells
of the innate immune system to engulf exogenous particles.
Phagocytosis can promote membrane biogenesis via the
activation of SREBP-1a and SREBP-2 (Castoreno et al.
2005). In addition, it has been reported that bacterial pore-
forming toxins can trigger cleavage and activation of
SREBP-1 and SREBP-2, probably through caspase-1,
which could aid in membrane repair (Gurcel et al. 2006).
Furthermore, it has been found that SREBP-1a can induce
expression of the anti-apoptotic gene Api6 when toxin is
present, which promotes cell survival (Im and Osborne
2012). In fission yeast, it was found that SREBP homologs
stimulated transcription of genes that are involved in
adaption to hypoxia in response to low oxygen levels
(Hughes et al. 2005). Several reports found SREBP to be
involved in cell cycle control. nSREBP-1 appears to be
hyperphosphorylated by cyclin-dependent kinase (CDK)1/
Cyclin B during mitosis, which stabilizes nSREBP. Fur-
thermore, inactivation of SREBP-1 arrested the cells in the
G1 phase of the cell cycle (Bengoechea-Alonso and
Ericsson 2006). In addition, expression of the major CDK
inhibitor p21 was found to be induced by SREBP-1 (Inoue
et al. 2005). Interestingly, miR33, located in the SREBP
gene locus, also appears to be involved in the regulation of
the cell cycle. miR33 inhibits CDK6 and cyclin D1 and
thus reduces cell cycle progression, with overactivation of
miR33 even leading to a cell cycle arrest in the G1 phase
(Cirera-Salinas et al. 2012). The roles of SREBP beyond
lipid metabolism have been reviewed in more detail in
recent reviews (Jeon and Osborne 2012; Shao and Espen-
shade 2012).
Conclusion
We previously described how literature review can be used
to obtain highly curated pathways for biological processes
(Adriaens et al. 2008; Jennen et al. 2010), which can be
used for data analysis in PathVisio (van Iersel et al. 2008).
The new interactive browsing functionality of WikiPath-
ways now allows the pathways themselves to be used as
interactive means to study relevant literature and database
information on the reactions and entities involved, their
known roles in biology and disease, relevant genetic vari-
ation, chemical properties, etcetera. The SREBP pathway
on WikiPathways described here is an example that makes
full use of this functionality.
The basic pathway of SREBP signaling has been well
described. When sterol levels are high, Insig retains the
SREBP–SCAP complex within the ER membrane. In case
of sterol depletion, the SREBP–SCAP complex interacts
with COPII proteins and migrates in COPII vesicles to the
Golgi apparatus. In the Golgi apparatus, SREBP is cleaved
and active nuclear SREBP is released. This nSREBP
migrates to the nucleus to activate target genes involved in
lipid metabolism. However, the regulation of the pathway
proves to be very complex and there are still many
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unanswered questions, especially regarding target genes
and regulation. Increasingly, links are being found between
the SREBP pathway and other regulators of lipid, protein,
and carbohydrate metabolism and overall energy homeo-
stasis: PUFAs are an example how diet influences the
SREBP pathway, the link found between glutamine and
SREBP suggests another link between amino acid metabo-
lism and lipid metabolism, the interaction of ATF6 and
SREBP-2 could imply that the synthesis of cholesterol is
slowed in case of energy stress through SREBP-2 inhibition.
Especially important to recognize are the links between
insulin, glucose, and SREBP, suggesting an important role
for SREBP in the pathology of current diseases, as obesity
and the metabolic syndrome. Combining and integrating the
growing knowledge on the SREBP pathway is essential, in
which biological pathway creation and curation can play a
major role.
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